-transparent.png){kind=logo}
Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
October 1993,
American journal of ophthalmology,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
June 1995,
Lancet (London, England),
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
December 1990,
The Journal of investigative dermatology,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
March 1993,
Journal of internal medicine,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
November 1988,
Lancet (London, England),
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
April 1998,
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
September 1986,
Seminars in oncology,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
June 1987,
Seminars in oncology,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
May 1988,
Klinische Wochenschrift,
R de Wit, and
P J Bakker, and
S A Danner, and
J Goudsmit, and
K H Veenhof
January 1991,
Journal of acquired immune deficiency syndromes,
